stockrowArcus Biosciences, Inc.
RCUS Healthcare Biotechnology
Arcus Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $247.0 million, down 4.26% from fiscal 2024.
- Revenue
- −65.4%
- EPS
- +21.3%
- Free cash flow
- +9.28%
- Total debt
- +4.08%
Quarter to September 2026, against a year earlier
Follow RCUS
Alert me
Arcus Biosciences, Inc. (RCUS) EBITDA
Arcus Biosciences, Inc.'s EBITDA for fiscal 2025 was −$389.0M, compared with −$345.0M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$488.0M. Over the past ten years it has ranged from −$389.0M (fiscal 2025) to $63.0M (fiscal 2021) — the current reading is the lowest in ten years. Arcus Biosciences, Inc. ranks 575th of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$389.0M | — |
| FY2024 | −$345.0M | — |
| FY2023 | −$351.0M | — |
| FY2022 | −$274.0M | — |
| FY2021 | $63.0M | — |
| FY2020 | −$121.0M | — |
| FY2019 | −$87.8M | — |
| FY2018 | −$52.9M | — |
| FY2017 | −$50.8M | — |
| FY2016 | −$16.9M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | −$96.0M | — |
| Mar 2026 | −$135.0M | — |
| Dec 2025 | −$114.0M | — |
| Sep 2025 | −$143.0M | — |
| 34 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| MBX MBX Biosciences, Inc. compare | −$117.7M |
| XNCR Xencor, Inc. compare | −$209.4M |
| PHVS Pharvaris N.V. compare | −$212.2M |
| NAMS NewAmsterdam Pharma Company N.V. compare | −$233.2M |
| ZLAB Zai Lab Limited Unsponsored ADR compare | −$253.7M |
| BEAM Beam Therapeutics Inc. compare | −$381.7M |
| RXRX Recursion Pharmaceuticals, Inc. compare | −$421.1M |
| IDYA IDEAYA Biosciences, Inc. compare | −$463.5M |
| RCUS Arcus Biosciences, Inc. | −$488.0M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on RCUS
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement